Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Kiniksa Pharmaceuticals is a biotechnology business based in the US. Kiniksa Pharmaceuticals shares (KNSA) are listed on the NASDAQ and all prices are listed in US Dollars. Kiniksa Pharmaceuticals employs 215 staff and has a trailing 12-month revenue of around $177 million.
Finder Award
SoFi Invest
Robinhood
tastyworks
| Latest market close | $13.99 |
|---|---|
| 52-week range | $7.36 - $17.20 |
| 50-day moving average | $15.34 |
| 200-day moving average | $12.00 |
| Wall St. target price | $22.20 |
| PE ratio | 6.9453 |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $2.01 |
Information on this page is for educational purposes only. Finder is not an advisor or brokerage service, and we don't recommend investors to trade specific stocks or other investments.
Finder is not a client of any featured partner. We may be paid a fee for referring prospective clients to a partner, though it is not a recommendation to invest in any one partner.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $13.99 from 2023-01-27
| 1 week (2023-01-23) | -0.07% |
|---|---|
| 1 month (2022-12-30) | -6.61% |
| 3 months (2022-10-31) | 22.50% |
| 6 months (2022-07-29) | 41.17% |
| 1 year (2022-01-31) | 24.58% |
|---|---|
| 2 years (2021-01-29) | -28.95% |
| 3 years (2020-01-31) | 14.71 |
| 5 years (2018-01-27) | N/A |
Valuing Kiniksa Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Kiniksa Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Kiniksa Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 7x. In other words, Kiniksa Pharmaceuticals shares trade at around 7x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
| Revenue TTM | $177 million |
|---|---|
| Gross profit TTM | $28.6 million |
| Return on assets TTM | -5.68% |
| Return on equity TTM | 47.68% |
| Profit margin | 80.53% |
| Book value | $5.52 |
| Market capitalisation | $970.7 million |
TTM: trailing 12 months
We're not expecting Kiniksa Pharmaceuticals to pay a dividend over the next 12 months.
Over the last 12 months, Kiniksa Pharmaceuticals's shares have ranged in value from as little as $7.36 up to $17.195. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Kiniksa Pharmaceuticals's is -0.0917. This would suggest that Kiniksa Pharmaceuticals's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Kiniksa Pharmaceuticals has bucked the trend.
Kiniksa Pharmaceuticals, Ltd. , a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda. .
Everything we know about the TXO Energy IPO, plus information on how to buy in.
Everything we know about the Brera IPO, plus information on how to buy in.
What you need to know about investing in the leading indicator for the overall US stock market.
Buying an IPO is as simple as buying any other stock, but not every trading platform offers IPO stocks.
Steps to owning and managing NVOS, with 24-hour and historical pricing before you buy.
Your simple and straightforward guide to ETFs, how they work and the different types available.
Find out how stock lending works, the extra income you could potentially earn and the risks you should be aware of. Plus, compare stock trading platforms that offer stock lending.
Everything we know about the SONDORS IPO, plus information on how to buy in.
Everything we know about the Bullfrog AI Holdings IPO, plus information on how to buy in.
Learn about stock analysis and how to use it to find the right company to buy.